Four patients were described whose skin appeared to have been severely scalded, although there had been no thermal burn. (The SCI® indicates that this paper has been cited in over 215 publications, making it the most-cited paper published in this journal.)

Alan Lyell
Department of Dermatology
Glasgow Royal Infirmary
Glasgow G4 0SF
Scotland

July 15, 1987

Nature lovers comb the valleys, fields, and woods of their neighbourhoods to identify flowers and birds and delight in them. So it was with me, when my eyes were opened to the world of skin disease by G.B. Dowling, Hugh Wallace, and Howard Whittle. Every clinic became, as it were, an expedition into the unfolding world of nature. To a person under such a spell an unidentifiable skin disease posed a challenge that demanded explanation or (if that were impossible) description.

I kept the first example of the “scalding disease” (seen at Cambridge) to myself for eight years, until I had found three more, two at Edinburgh and one at Aberdeen. I chose the name “toxic epidermal necrolysis” (TEN) to describe, as nearly as possible, my ideas about the disease's cause, site, pathology, and clinical picture. (Necrolysis was a new word invented for the occasion, combining necrosis and epidermolysis.)

I have followed the growth and career of TEN closely and have played a part in its unfolding, which is still far from complete. It proved to be a mixture of several conditions, for each patient turned out to have a different disease. One case, who had what would now be diagnosed as the staphylococcal scalded skin syndrome (SSSS), had suffered the effects of staphylococcal epidermolytic toxin, a substance whose discovery in 1970 liberated a flood of research and illuminated many clinical mysteries.

The patient from Aberdeen displayed that severe type of drug reaction that most dermatologists equate with TEN today, although drug-induced epidermal necrolysis would be a better name. But the Cambridge patient had repeated attacks, presumably self-inflicted, of a generalised bullous fixed drug eruption—an entirely different type of reaction that has been clearly distinguished by Kirsti Kauppinen.

The fourth patient, who did not have the histopathology of SSSS and had no apparent connection with drugs, was classified temporarily as “idiopathic.”

TEN, alias Lyell’s disease, provided me with a passport to the dermatologists of the world and brought me an unmerited aura of fame. Nevertheless, it is frustrating to be typecast as if I knew nothing else. It saddens me that my name should be associated with death and distress; I once appeared in the US as an expert witness—a form of stress that precipitated an acute attack of gout, yet I am reluctant to take allopurinol regularly in case I should die of Lyell’s disease! As for the name TEN, it should be allowed to expire quietly, eclipsed by expanding knowledge of its component parts.